ClinicalTrials.gg
CompletedNCT01431950Updated Jan 9, 2017Results posted

Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

A Phase 3 interventional study of fluticasone furoate and albuterol/salbutamol in Asthma, sponsored by GlaxoSmithKline. Completed at 40 sites in 6 countries. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
12 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
17th of 40
238 · median 102
Started
2011
with 3 others
Phase 3
14 of 40
none open now
Registered
18th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 17th largest by enrollment, is one of 4 that started in 2011, is one of 14 in phase 3, and was the 18th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

A randomised, double-blind, multi-centre study to evaluate the efficacy and safety of two doses of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents currently receiving mid to high strength inhaled corticosteroids.

Read the detailed description

This will be a multi-centre, randomised, double-blind, parallel-group study. Subjects meeting all the inclusion criteria and none of the exclusion criteria during Visit 1 (screening visit) will enter a four week Run-In period during which they will remain on their baseline ICS medication. In addition, all subjects will be provided with albuterol/salbutamol for relief of asthma symptoms. Subjects failing screening will not be eligible for re-screening. During the Run-In and double-blind treatment periods subjects will maintain an electronic daily diary to record morning and evening Peak Expiratory Flow (PEF), asthma symptom score and rescue albuterol/salbutamol use. Subjects will receive a contact (Phone Contact 1/optional office visit (1b)) during Run-In to reinforce compliance with Run-In medication and diary monitoring. Those subjects who meet the eligibility criteria at the end of the Run-In period will be stratified in an approximately 1:1 ratio according to their baseline FEV1 as a percentage of predicted normal - one stratum for those with FEV1 percent predicted ≥40% to ≤65% and one for those with FEV1 percent predicted >65% to ≤90%. Once stratified, subjects will be randomised to one of the following treatments and enter into a 24 week double-blind treatment period:1) Fluticasone furoate 100mcg once daily in the evening or 2) Fluticasone furoate 200mcg once daily in the evening.

Subjects will then attend 6 on-treatment visits at Visits 3, 4, 5, 6, 7 and 8 (Weeks 2, 4, 8, 12, 18 and 24 respectively). All visits including Visit 1 must be conducted in the evening between 5 PM and 11 PM. Subjects will receive treatment for 24 weeks. Twenty four hour urinary cortisol assessments will be collected at the end of Run-In (Visit 2) and at end of treatment (Visit 8) visits. A follow-up contact will be performed 1-week after completing study medication (Visit 9). Subjects will participate in the study for up to a maximum of 29 weeks (including screening, treatment and follow-up contact). In addition, partially used NDPIs will be collected in a subset of subjects. For subjects who have consented for pharmacogenetics, a blood sample will also be taken for pharmacogenetic analysis.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • fluticasone furoate
04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks prior to first visit
  • Both genders; females of child bearing potential must be willing to use appropriate
  • Pre-bronchodilator of 40-90% predicted
  • Reversibility FEV1 of at least 12% and 200mLs
  • Current asthma therapy that includes inhaled for at least 4 weeks prior to first visit

Exclusion criteria

Exclusion Criteria:

  • History of life threatening asthma
  • Respiratory infection or candidiasis
  • Asthma exacerbation requiring OCS within last 4 weeks or overnight hospital stay within the last 3 months
  • Concurrent respiratory disease or other disease that would confound study participation of affect subject safety
  • Allergies to study drugs, study drug , medications related to study drugs
  • Taking another medication or medication prohibited for use during the study
  • Previous treatment with FF or FF/VI in a phase II or III study
  • Night shift workers
  • Children in care
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    FF 100mcg once daily

    Inhaled corticosteroid (ICS)

    Drug: fluticasone furoate · Drug: albuterol/salbutamol

  • Experimental
    FF 200mcg once daily

    Inhaled corticosteroid

    Drug: fluticasone furoate · Drug: albuterol/salbutamol

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Evening clinic visit FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the Week 24 clinic visit. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 were measured electronically by spirometry in the evening at the Baseline through Week 24 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 2. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing, pre-dose, post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing value.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period

    The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. A 24-hour period was considered as missing if both day time and night time values were missing or if one of the day time or night time values were missing and the other value indicated no use of rescue medication. The Baseline value is the average of the values over the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: From Baseline up to Week 24

  2. Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period

    PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough PM PEF over the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: From Baseline up to Week 24

  3. Change From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period

    PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: From Baseline up to Week 24

  4. Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 24-week Treatment Period

    Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. A 24-hour period was considered as missing if both the day time and night time data were missing or if one was symptom-free but the other was missing. The Baseline value was the average of the values of the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

    Time frame: From Baseline up to Week 24

07

Results

Posted Sep 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneFF 100 µg ODFF 200 µg OD
Started119119
Completed100104
Not completed1915
Withdrew: Study site closed/terminated73
Withdrew: Withdrawal by subject43
Withdrew: Protocol violation23
Withdrew: Adverse event22
Withdrew: Physician decision21
Withdrew: Lack of efficacy21
Withdrew: Lost to follow-up01
Withdrew: Met protocol-defined stopping criteria01

Outcome measures

PrimaryChange From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Evening clinic visit FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the Week 24 clinic visit. Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 were measured electronically by spirometry in the evening at the Baseline through Week 24 clinic visits. The highest of 3 technically acceptable measurements was recorded. Baseline was the pre-dose value obtained at Visit 2. Change from Baseline was calculated as the Week 24 value minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing, pre-dose, post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing value.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
LitersFF 100 µg ODFF 200 µg OD
Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period0.208 ± 0.04170.284 ± 0.0411
Statistical analysis
  • FF 100 µg OD vs FF 200 µg OD · Mean difference (final values): 0.077 · 95% CI -0.039 to 0.192
SecondaryChange From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period

The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary). A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. A 24-hour period was considered as missing if both day time and night time values were missing or if one of the day time or night time values were missing and the other value indicated no use of rescue medication. The Baseline value is the average of the values over the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
From Baseline up to Week 24
Reported as:
Least squares mean · Percentage of rescue-free 24-hr periods
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period
Percentage of rescue-free 24-hr periodsFF 100 µg ODFF 200 µg OD
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period21.3 ± 3.0523.1 ± 3.03
SecondaryChange From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period

PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough PM PEF over the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
From Baseline up to Week 24
Reported as:
Least squares mean · Liters/minute (L/min)
Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period
Liters/minute (L/min)FF 100 µg ODFF 200 µg OD
Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period5.9 ± 3.267.2 ± 3.25
SecondaryChange From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period

PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
From Baseline up to Week 24
Reported as:
Least squares mean · L/min
Change From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period
L/minFF 100 µg ODFF 200 µg OD
Change From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period13.4 ± 3.2213.2 ± 3.20
SecondaryChange From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 24-week Treatment Period

Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement. A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. A 24-hour period was considered as missing if both the day time and night time data were missing or if one was symptom-free but the other was missing. The Baseline value was the average of the values of the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.

Time frame:
From Baseline up to Week 24
Reported as:
Least squares mean · Percentage of symptom-free 24-hr periods
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 24-week Treatment Period
Percentage of symptom-free 24-hr periodsFF 100 µg ODFF 200 µg OD
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 24-week Treatment Period17.5 ± 2.8019.6 ± 2.79

Adverse events

Collected over On-treatment adverse events (AEs), defined as those events occurring while participants were on treatment, up to and including the day after the last dose (up to 24 weeks), are reported.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF 100 µg OD—3/119 (2.5%)52/119 (43.7%)
FF 200 µg OD—4/119 (3.4%)49/119 (41.2%)
Most frequent serious events
Most frequent serious events
EventFF 100 µg ODFF 200 µg OD
ChondromalaciaMusculoskeletal and connective tissue disorders1/1190/119
ChondropathyMusculoskeletal and connective tissue disorders0/1191/119
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1191/119
SpondylolisthesisMusculoskeletal and connective tissue disorders0/1191/119
AbscessInfections and infestations0/1191/119
Acute sinusitisInfections and infestations1/1190/119
Cholecystitis acuteHepatobiliary disorders0/1191/119
ThymomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1191/119
Cystitis haemorrhagicRenal and urinary disorders1/1190/119
Most frequent other events
Most frequent other events
EventFF 100 µg ODFF 200 µg OD
NasopharyngitisInfections and infestations14/11915/119
HeadacheNervous system disorders12/11915/119
BronchitisInfections and infestations14/1198/119
InfluenzaInfections and infestations5/1198/119
SinusitisInfections and infestations8/1195/119
PharyngitisInfections and infestations7/1194/119
Upper respiratory tract infectionInfections and infestations2/1197/119
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/1195/119
Rhinitis allergicRespiratory, thoracic and mediastinal disorders5/1192/119
Back painMusculoskeletal and connective tissue disorders4/1194/119

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF 100 µg ODFF 200 µg ODTotal
Mean46.6 ± 15.4145.1 ± 15.7845.9 ± 15.58
Gender
Gender(Participants)FF 100 µg ODFF 200 µg ODTotal
Female8179160
Male384078
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF 100 µg ODFF 200 µg ODTotal
African American/African Heritage (HER)549
Central/South Asian HER101
Japanese/East Asian HER /South East Asian HER033
Native Hawaiian or other Pacific Islander101
White101100201
American Indian or Alaska Native & White111223
08

Study locations

40 sites
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Clearwater, Florida 33756, United States
  • GSK Investigational Site
    Albany, Georgia 31707, United States
  • GSK Investigational Site
    Lexington, Kentucky 40503, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    Bethesda, Maryland 20814, United States
  • GSK Investigational Site
    Plymouth, Minnesota 55441, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89119, United States
  • GSK Investigational Site
    Brick, New Jersey 08724, United States
  • GSK Investigational Site
    Utica, New York 13502, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45242, United States
  • GSK Investigational Site
    Toledo, Ohio 43617, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1121ABE, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, 4000, Argentina
  • GSK Investigational Site
    Puente Alto - Santiago, Región Metro De Santiago 8207257, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500800, Chile
  • GSK Investigational Site
    Valparaiso, Valparaíso 2341131, Chile
  • GSK Investigational Site
    Aigrefeuille Sur Maine, 44140, France
  • GSK Investigational Site
    Bourg Des Comptes, 35890, France
  • GSK Investigational Site
    Chalons en Champagne, 51000, France
  • GSK Investigational Site
    Laon, 02000, France
  • GSK Investigational Site
    Nantes, 44300, France
  • GSK Investigational Site
    Vannes, 56000, France
  • GSK Investigational Site
    Villahermosa, Tabasco 86100, Mexico
  • GSK Investigational Site
    Mexico City, 07760, Mexico
  • GSK Investigational Site
    Belgorod, 308007, Russian Federation
  • GSK Investigational Site
    Kazan, 420015, Russian Federation
  • GSK Investigational Site
    Novokuznetsk, 654063, Russian Federation
  • GSK Investigational Site
    Penza, 440067, Russian Federation
  • GSK Investigational Site
    Pyatigorsk, 357538, Russian Federation
09

References and documents

Publications

  • O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x. PubMed 27881132 ↗
  • Woodcock A, Lotvall J, Busse WW, Bateman ED, Stone S, Ellsworth A, Jacques L. Efficacy and safety of fluticasone furoate 100 mug and 200 mug once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med. 2014 Jul 9;14:113. doi: 10.1186/1471-2466-14-113. PubMed 25007865 ↗
  • Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014 Jun 26;24:14019. doi: 10.1038/npjpcrm.2014.19. No abstract available. PubMed 24966061 ↗
  • Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013 Dec 7;13:72. doi: 10.1186/1471-2466-13-72. PubMed 24314123 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 11 months after primary completion. A results delay was requested in Mar 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2011
First posted
Sep 12, 2011
Start
Sep 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results delay requested
Mar 14, 2013
Results first posted
Sep 3, 2014
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01431950
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 12, 2011
Start date
Sep 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Sep 3, 2014
Last update
Jan 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion